CONSEQUENCES AND VALIDITY OF AN EMPIRICAL ESTIMATION OF THE NICE COST EFFECTIVENESS THRESHOLD

Author(s)

Grobler M1, Lothgren M2
1Amgen Inc., North Ryde, Australia, 2Amgen (Europe) GmbH, Zug, Switzerland

Presentation Documents

OBJECTIVES: to assess the validity of the key findings and explore the potential consequences of the 2015 Claxton et al paper “Methods for the Estimation of the NICE Cost Effectiveness Threshold”.

METHODS: RESULTS: CONCLUSIONS:

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

HT1

Topic

Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes

Disease

Multiple Diseases

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×